Medicines labeled for the same conditions
Alternatives to cilastatin and imipenem and relebactam
12 other medicines are given the same way (intravenous) and in the same FDA class as cilastatin and imipenem and relebactam or labeled mainly for the same use (urinary tract infections); 3 are in its class, renal dehydropeptidase inhibitors: avibactam and ceftazidime, ceftolozane and tazobactam and meropenem and vaborbactam; the others include 5 cephalosporin antibacterials and 2 tetracycline-class drugs (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as cilastatin and imipenem and relebactam?
Urinary tract infections lists all 39 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Cilastatin and imipenem and relebactamrenal dehydropeptidase inhibitor | this medicine | none listed | n/a | No | A presentation being discontinued |
| Avibactam and ceftazidimebeta lactamase inhibitor · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Ceftolozane and tazobactambeta lactamase inhibitor · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Meropenem and vaborbactampenem antibacterial · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Doxycyclinetetracycline-class drug | Urinary tract infections | 20 labelers | n/a | No | A presentation being discontinued |
| Cefazolincephalosporin antibacterial | Urinary tract infections | 7 labelers | $1.07 per vial 1 g vial | No | No current entry |
| Cefepimecephalosporin antibacterial | Urinary tract infections | 8 labelers | n/a | No | A presentation being discontinued |
| Ceftriaxonecephalosporin antibacterial | Urinary tract infections | 7 labelers | $1.44 per vial 1 g vial | No | No current entry |
| Plazomicin | Urinary tract infections | none listed | n/a | Yes | No current entry |
| Cefepime and zidebactamcephalosporin antibacterial | Urinary tract infections | none listed | n/a | No | No current entry |
| Cefiderocolcephalosporin antibacterial | Urinary tract infections | none listed | n/a | No | No current entry |
| Fosfomycin | Urinary tract infections | none listed | n/a | No | No current entry |
| Minocyclinetetracycline-class drug | Urinary tract infections | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Cilastatin and imipenem and relebactam: the full record
- label, generics, price, shortages, recalls